Chargement en cours...
BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors
We present a patient with BRAF-V600E mutant papillary craniopharyngioma successfully treated with combination BRAF (dabrafenib 150 mg twice daily) and MEK (trametinib 2 mg daily) inhibitors after her unresectable tumor proved refractory to radiation. Serial brain MRIs and PET revealed marked tumor r...
Enregistré dans:
| Publié dans: | CNS Oncol |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Future Medicine Ltd
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6020871/ https://ncbi.nlm.nih.gov/pubmed/28425764 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/cns-2016-0034 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|